Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
Cyclin-Dependent Kinase Inhibitor p21
/ antagonists & inhibitors
Gene Expression Regulation, Neoplastic
/ drug effects
Histone Deacetylase Inhibitors
/ pharmacology
Humans
Hydroxamic Acids
/ pharmacology
Multiple Myeloma
/ drug therapy
Tumor Suppressor Protein p53
/ genetics
Multiple myeloma
apoptosis
gene expression
myeloma cell lines
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
05
06
2020
revised:
26
06
2020
accepted:
03
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA), were analyzed in multiple myeloma cell lines RPMI8226 and U266 with differing TP53 status using gene-expression analysis. Enhanced expression of cyclin-dependent kinase inhibitor 1A (CDKN1A/p21 SAHA appears to be a potentially effective pro-apoptotic and anticancer drug with universal application in the treatment of heterogeneous populations of multiple myeloma cells.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood.
MATERIALS AND METHODS
METHODS
Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA), were analyzed in multiple myeloma cell lines RPMI8226 and U266 with differing TP53 status using gene-expression analysis.
RESULTS
RESULTS
Enhanced expression of cyclin-dependent kinase inhibitor 1A (CDKN1A/p21
CONCLUSION
CONCLUSIONS
SAHA appears to be a potentially effective pro-apoptotic and anticancer drug with universal application in the treatment of heterogeneous populations of multiple myeloma cells.
Identifiants
pubmed: 32878786
pii: 40/9/4979
doi: 10.21873/anticanres.14501
doi:
Substances chimiques
Antineoplastic Agents
0
CDKN1A protein, human
0
Cyclin-Dependent Kinase Inhibitor p21
0
Histone Deacetylase Inhibitors
0
Hydroxamic Acids
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4979-4987Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.